What is the expected growth forecast for the Macular Degeneration (AMD) market

The market is expected to grow at a CAGR of 7.8% from 2023 to 2028.

What are the key drivers of the Macular Degeneration (AMD) and Other Retinal Diseases market

Increasing prevalence of retinal diseases and advancements in treatment options are key drivers.

What are the major challenges faced by the Macular Degeneration (AMD) market

High treatment costs and limited access to healthcare in developing regions are major challenges.

Which regions are the leaders in the Macular Degeneration (AMD) and Other Retinal Diseases market

North America and Europe are the leading regions due to high prevalence and awareness.

Who are the top companies in the Macular Degeneration (AMD) market

Novartis, Bayer, and Regeneron are among the top companies developing innovative treatments.

What are the future opportunities in the Macular Degeneration (AMD) and Other Retinal Diseases market

Emerging markets and innovative technologies offer significant future outlook and growth opportunities.

How is technology impacting the Macular Degeneration (AMD) and Other Retinal Diseases market

Advances in gene therapy and stem cell technology are transforming the future outlook of the market.

What is the current regulatory landscape for the Macular Degeneration (AMD) market

Stringent regulations and safety protocols are in place to ensure efficacy and safety of treatments.

Macular Degeneration (AMD) and Other Retinal Diseases Size, Share & Forecast Analysis 2025–2033

Macular Degeneration (AMD) and Other Retinal Diseases by Application (Hospital, Clinic, Other), by Types (Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy(DR), Retinal Vein Occlusion, Wet Age-Related Macular Degeneration (wAMD), Dry Age-Related Macular Degeneration (dAMD), Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Macular Degeneration (AMD) and Other Retinal Diseases Market Overview

The Macular Degeneration (AMD) and Other Retinal Diseases market is a critical segment of the healthcare industry, with significant relevance in the treatment and management of vision-related disorders. As the global Macular Degeneration (AMD) and Other Retinal Diseases market size is estimated to be around $11.8 billion, the growth outlook and market forecast suggest a promising future, driven by an increasing prevalence of retinal diseases and the development of innovative therapies, ultimately contributing to industry expansion. The scope of this market encompasses various synonyms, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, among others.

Loading chart…

The Macular Degeneration (AMD) and Other Retinal Diseases market is expected to grow at a CAGR of 7.5% during the forecast period, driven by macro drivers such as an aging population, increasing healthcare expenditure, and advancements in treatment options. Key forces shaping the industry include technology shifts towards minimally invasive procedures, regulations supporting innovative drug development, and consumer behavior emphasizing preventive care. The largest region in this market is North America, while the fastest-growing region is Asia Pacific, driven by rising awareness and improving healthcare infrastructure. As the market continues to evolve, it is crucial for stakeholders to stay informed about the latest trends and developments to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	23.19 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Regeneron Pharmaceuticals; Bayer HealthCare; Novartis; Roche; Kanghong Pharma; Merck; Allergan; Santen Pharmaceutical; GlaxoSmithKline Pharmaceuticals; Pfizer; Acucela; Valent Pharmaceuticals; IVERIC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Macular Degeneration (AMD) and Other Retinal Diseases market is poised for significant growth, driven by factors such as an aging population, increased prevalence of retinal diseases, and advances in treatment options. The Macular Degeneration (AMD) and Other Retinal Diseases market size is expected to expand substantially over the forecast period, with a growth forecast that underscores the opportunities for industry players to develop innovative therapies and diagnostic tools.

Growth Drivers2 items

Increasing demand for effective treatments and rising awareness about retinal diseases are driving the growth of the Macular Degeneration (AMD) and Other Retinal Diseases market, with pharmaceutical companies investing heavily in research and development to address unmet medical needs.

Advances in gene therapy, stem cell therapy, and other novel approaches are expected to contribute to the growth of the Macular Degeneration (AMD) and Other Retinal Diseases market, as these technologies hold promise for improving treatment outcomes and patient quality of life.

Restraints2 items

High development costs, stringent regulatory requirements, and reimbursement challenges are key restraints in the Macular Degeneration (AMD) and Other Retinal Diseases market, limiting the ability of companies to bring new treatments to market and recoup their investments.

The complexity of retinal diseases and the need for personalized medicine approaches can also hinder growth in the Macular Degeneration (AMD) and Other Retinal Diseases market, as a one-size-fits-all approach may not be effective for all patients.

Opportunities2 items

The growing demand for minimally invasive and non-invasive diagnostic and therapeutic procedures presents opportunities for companies to develop innovative solutions that improve patient outcomes and enhance the overall efficiency of care in the Macular Degeneration (AMD) and Other Retinal Diseases market.

Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers can facilitate the development of new treatments and drive growth in the Macular Degeneration (AMD) and Other Retinal Diseases market, enabling the sharing of expertise, resources, and risk.

Challenges2 items

The Macular Degeneration (AMD) and Other Retinal Diseases market faces challenges related to patient access and affordability, particularly in low- and middle-income countries where healthcare resources are limited and out-of-pocket expenses can be prohibitive.

The need for long-term follow-up and monitoring of patients with retinal diseases can also pose challenges in the Macular Degeneration (AMD) and Other Retinal Diseases market, requiring significant investments in healthcare infrastructure and personnel to support the delivery of high-quality care.

Market Segmentation

Loading chart…

The Macular Degeneration (AMD) and Other Retinal Diseases market can be segmented based on Application and Types. The Application segment includes various uses of treatments and therapies for Macular Degeneration (AMD) and Other Retinal Diseases, which contribute to the overall market size. This segment is further divided into subtypes, such as [object Object] and [object Object], which are crucial in understanding the Macular Degeneration (AMD) and Other Retinal Diseases segmentation.

The Types segment of the Macular Degeneration (AMD) and Other Retinal Diseases market includes different categories of diseases, such as Dry AMD and Wet AMD, as well as other retinal diseases like Diabetic Retinopathy and Retinal Vein Occlusion. Each of these types has distinct characteristics, symptoms, and treatment options, making them essential components of the market taxonomy. Understanding these segments is vital for analyzing the market and identifying opportunities for growth.

Macular Degeneration (AMD) and Other Retinal Diseases Segmentation Breakdown12 items

Application

Hospital

Clinic

Other

Types

Macular Degeneration

Diabetic Macular Edema

Diabetic Retinopathy(DR)

Retinal Vein Occlusion

Wet Age-Related Macular Degeneration (wAMD)

Dry Age-Related Macular Degeneration (dAMD)

Other

Regional Insights

Loading chart…

The Macular Degeneration (AMD) and Other Retinal Diseases market growth is anticipated to vary across regions, with North America emerging as the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of advanced treatments and rising investments in healthcare infrastructure.

Key drivers in North America include a mature ecosystem, high demographics awareness, and significant policies supporting research and development. In Europe, factors such as favorable policies, rising adoption of novel therapies, and growing investments in medical research contribute to market growth. Asia Pacific's growth is fueled by expanding infrastructure, increasing adoption of modern treatments, and a large patient population.

Latin America's regional forecast indicates steady growth, driven by improving infrastructure, rising adoption of innovative therapies, and growing investments in healthcare. The Middle East & Africa region is expected to experience moderate growth, influenced by developing ecosystem maturity, increasing adoption of advanced treatments, and government policies supporting healthcare development.

Competitive Landscape

The Macular Degeneration (AMD) and Other Retinal Diseases competitive landscape is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is characterized by high competition, with companies focusing on product differentiation and strategic partnerships to gain market share. Understanding the Macular Degeneration (AMD) and Other Retinal Diseases competitive landscape is crucial for companies to develop effective strategies and stay competitive.

Companies in this market employ various strategies, including M&A, partnerships, product launches, expansion, R&D, and localization, to differentiate themselves and gain a competitive edge. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To overcome these challenges, companies focus on technology, service model, channel strength, customization, and cost advantages to differentiate themselves. The following companies have adopted distinct strategies:

Regeneron Pharmaceuticals: innovation pipeline

Bayer HealthCare: regional expansion

Novartis: premium pricing

Roche: OEM tie-ups

Kanghong Pharma: local manufacturing

Merck: vertical integration

Key Macular Degeneration (AMD) and Other Retinal Diseases Companies13 items

Regeneron Pharmaceuticals

Bayer HealthCare

Novartis

Roche

Kanghong Pharma

Merck

Allergan

Santen Pharmaceutical

GlaxoSmithKline Pharmaceuticals

Pfizer

Acucela

Valent Pharmaceuticals

IVERIC

Market Ecosystem

The Macular Degeneration (AMD) and Other Retinal Diseases ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers, midstream integrators and manufacturers, to downstream channels and end users. Value creation and capture occur at each stage, from research and development to diagnosis, treatment, and patient care. Understanding the ecosystem's boundaries and interactions is crucial for conducting a comprehensive value chain analysis.

Raw material/component suppliers — providing medical equipment and pharmaceuticals

Technology providers — developing diagnostic and therapeutic technologies

OEMs / manufacturers — producing medical devices and equipment

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering maintenance and support services

End users / buyers — healthcare providers and patients seeking treatment

Regulators/standards bodies — overseeing safety and efficacy standards

In the Macular Degeneration (AMD) and Other Retinal Diseases ecosystem, control points are primarily held by regulatory bodies, healthcare providers, and technology developers, who influence adoption through standards, approvals, and partnerships. Dependency risks arise from input constraints, such as limited access to certain technologies or raw materials, as well as regional differences in standards and approvals. Switching costs and interoperability requirements also impact the ecosystem, as healthcare providers and patients may face challenges in transitioning between different treatments or technologies. Furthermore, the ecosystem differs by region, with varying levels of access to healthcare services, technologies, and treatments.

Recent Industry Insights

The Macular Degeneration (AMD) and Other Retinal Diseases industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been several strategic partnerships, such as the collaboration between biotechnology companies to develop innovative treatments for retinal diseases. Additionally, mergers and acquisitions have also been prominent, with major pharmaceutical companies acquiring smaller firms to expand their product portfolios and strengthen their presence in the market.

Recent product launches, including gene therapies and advanced implantable devices, have also been observed, showcasing the industry's shift towards more innovative and personalized treatment options. Furthermore, regulatory changes, such as the FDA's approval of new treatments, have contributed to the growth of the Macular Degeneration (AMD) and Other Retinal Diseases market. The industry has also seen a significant shift in consumer trends, with an increased focus on preventive care and early disease detection.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Macular Degeneration (AMD) and Other Retinal Diseases market outlook. The market attractiveness is moderate, driven by an aging population and increasing prevalence of retinal diseases. Competitive intensity is high, with several key players investing in research and development. The long-term outlook is promising, with advancements in treatment options and innovative therapies. The innovation landscape is rapidly evolving, with a focus on gene therapies and combination treatments. However, demand-supply balance is a concern, with limited access to novel therapies in certain regions. Key risk factors include regulatory challenges, pricing pressures, and the need for personalized treatment approaches.

11 items

1. Executive Summary

2. Macular Degeneration (AMD) and Other Retinal Diseases Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Other

6.2. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Macular Degeneration

6.2.2. Diabetic Macular Edema

6.2.3. Diabetic Retinopathy(DR)

6.2.4. Retinal Vein Occlusion

6.2.5. Wet Age-Related Macular Degeneration (wAMD)

6.2.6. Dry Age-Related Macular Degeneration (dAMD)

6.2.7. Other

6.3. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Competition by Key Manufacturers

8.1. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Macular Degeneration (AMD) and Other Retinal Diseases: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Regeneron Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer HealthCare

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Roche

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Kanghong Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Merck

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Allergan

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Santen Pharmaceutical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. GlaxoSmithKline Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Pfizer

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Acucela

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Valent Pharmaceuticals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. IVERIC

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Macular Degeneration (AMD) and Other Retinal Diseases Market

Figure 4: Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Drivers

Figure 5: Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Challenges

Figure 6: Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Trends

Figure 7: Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Opportunity

Figure 8: Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Restraint

Figure 9: Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Value (USD Million) By Region

Figure 15: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Value (USD Million) By Region

Figure 23: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Value (USD Million) By Region

Table 10: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Macular Degeneration (AMD) and Other Retinal Diseases Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Regeneron Pharmaceuticals Basic Information And Sales Area

Table 31: Regeneron Pharmaceuticals. Products Portfolio

Table 32: Bayer HealthCare Basic Information And Sales Area

Table 33: Bayer HealthCare. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Roche Basic Information And Sales Area

Table 37: Roche. Products Portfolio

Table 38: Kanghong Pharma Basic Information And Sales Area

Table 39: Kanghong Pharma. Products Portfolio

Table 40: Merck Basic Information And Sales Area

Table 41: Merck. Products Portfolio

Table 42: Allergan Basic Information And Sales Area

Table 43: Allergan. Products Portfolio

Table 44: Santen Pharmaceutical Basic Information And Sales Area

Table 45: Santen Pharmaceutical. Products Portfolio

Table 46: GlaxoSmithKline Pharmaceuticals Basic Information And Sales Area

Table 47: GlaxoSmithKline Pharmaceuticals. Products Portfolio

Table 48: Pfizer Basic Information And Sales Area

Table 49: Pfizer. Products Portfolio

Table 50: Acucela Basic Information And Sales Area

Table 51: Acucela. Products Portfolio

Table 52: Valent Pharmaceuticals Basic Information And Sales Area

Table 53: Valent Pharmaceuticals. Products Portfolio

Table 54: IVERIC Basic Information And Sales Area

Table 55: IVERIC. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Value (USD Million) By Region

Table 61: Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Macular Degeneration (AMD) and Other Retinal Diseases Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	23.19 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Regeneron Pharmaceuticals; Bayer HealthCare; Novartis; Roche; Kanghong Pharma; Merck; Allergan; Santen Pharmaceutical; GlaxoSmithKline Pharmaceuticals; Pfizer; Acucela; Valent Pharmaceuticals; IVERIC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Macular Degeneration (AMD) and Other Retinal Diseases Segmentation Breakdown12 items

Application

Hospital

Clinic

Other

Types

Macular Degeneration

Diabetic Macular Edema

Diabetic Retinopathy(DR)

Retinal Vein Occlusion

Wet Age-Related Macular Degeneration (wAMD)

Dry Age-Related Macular Degeneration (dAMD)

Other

Regional Insights

Loading chart…

Competitive Landscape

Regeneron Pharmaceuticals: innovation pipeline

Bayer HealthCare: regional expansion

Novartis: premium pricing

Roche: OEM tie-ups

Kanghong Pharma: local manufacturing

Merck: vertical integration

Key Macular Degeneration (AMD) and Other Retinal Diseases Companies13 items

Regeneron Pharmaceuticals

Bayer HealthCare

Novartis

Roche

Kanghong Pharma

Merck

Allergan

Santen Pharmaceutical

GlaxoSmithKline Pharmaceuticals

Pfizer

Acucela

Valent Pharmaceuticals

IVERIC

Market Ecosystem

Raw material/component suppliers — providing medical equipment and pharmaceuticals

Technology providers — developing diagnostic and therapeutic technologies

OEMs / manufacturers — producing medical devices and equipment

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering maintenance and support services

End users / buyers — healthcare providers and patients seeking treatment

Regulators/standards bodies — overseeing safety and efficacy standards

Recent Industry Insights

Analyst Overview

Table of Contents